


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1) (Previously presented) An imaging agent which comprises a synthetic MSRA antagonist labelled with an imaging moiety, wherein the synthetic MSRA antagonist is a sulphonamidobenzamide compound of Formula (II):



wherein

z is 0, 1 or 2;

R¹, R², R⁴⁻⁷, R⁹⁻¹¹, R¹³ and R¹⁴ are chosen from hydrogen, C₁₋₆ alkyl, hydroxy, carboxy, amino or halogen;

R², R⁸ and R¹² are all halogen wherein at least one of R², R⁸ and R¹² is ¹²³I or ¹⁸F; and wherein the imaging moiety can be detected externally in a non-invasive manner following administration of said labelled synthetic MSRA antagonist to the mammalian body *in vivo*.

- 2-5) (Cancelled)

Appl. No. 10/537,103
Reply to Office Action of January 3, 2011

6) (Withdrawn) The imaging agent of claim 1, wherein said imaging moiety is selected from:

- (i) a gamma-emitting radioactive halogen;
- (ii) a positron-emitting radioactive non-metal;

7) (Cancelled)

8) (Cancelled)

9) (Cancelled)

10) (Cancelled)

11) (Withdrawn) The imaging agent of claim 6, wherein the gamma-emitting radioactive halogen is a radioactive isotope of iodine.

12) (Withdrawn) The imaging agent of claim 11, wherein the radioactive isotope of iodine is chosen from ^{123}I or ^{131}I .

13) (Cancelled)

14) (Withdrawn) The imaging agent of claim 13, wherein the positron-emitting radioactive non-metal is ^{18}F .

15) (Cancelled)

16) (Cancelled)

17) (Cancelled)

18) (Cancelled)

19) (Cancelled)

20) (Cancelled)

- 21) (Previously presented) A pharmaceutical composition comprising the imaging agent of claim 1, together with a biocompatible carrier, in a form suitable for mammalian administration.
- 22) (Original) The pharmaceutical composition of claim 21 for use in the diagnostic imaging of cardiovascular disease.
- 23) (Previously presented) The pharmaceutical composition of claim 21 for use in the diagnostic imaging of atherosclerotic plaques, coronary artery disease, thrombosis, transient ischaemia or renal disease.
- 24) (Original) The pharmaceutical composition of claim 23 for use in the diagnostic imaging of atherosclerotic plaques.
- 25) (Original) The pharmaceutical composition of claim 24 for use in the diagnostic imaging of unstable atherosclerotic plaques.
- 26) (Previously presented) A kit for the preparation of the pharmaceutical composition of claim 21, comprising a precursor of the imaging agent of claim 1.
- 27) – 34) (Cancelled)